Condition: Relapsed or Refractory Mantle Cell Lymphoma (MCL) · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
This description comes directly from the study's public registry record.
Alexia Lu · 010-66609745 · CO_HGRAC@innocarepharma.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Chengdu, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, Guangxi, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07082686